Jaguar LAA, Inc. Announces Acquisition of Assets Related to the Laminar Program

Jaguar LAA, Inc., a privately held medical device company based in Santa Rosa, California, has acquired assets related to the Laminar program from Johnson & Johnson for an undisclosed amount. This transaction, announced on September 11, 2026, positions Jaguar to advance its differentiated approach to left atrial appendage (LAA) closure, specifically targeting patients with non-valvular atrial fibrillation (AFib). The acquisition consolidates key assets of the Laminar program with the development team responsible for its innovation, enabling Jaguar to build on previous clinical and development work.

The Laminar program focuses on addressing the LAA, a critical area in cardiology associated with thrombus formation in patients suffering from non-valvular AFib. This heart rhythm disorder significantly increases the risk of stroke, making effective treatment options essential. The Laminar technology employs a catheter-based approach that utilizes rotational motion to close the LAA while minimizing device exposure within the left atrium. This innovative method is positioned as a potential game-changer in the management of AFib, offering a less invasive option for patients.

Jaguar LAA was formed in collaboration with Santé Ventures and members of the Laminar management team, with Santé leading the financing and formation of the company. The strategic acquisition from Johnson & Johnson not only strengthens Jaguar’s portfolio but also allows for a focused effort on advancing the Laminar program through subsequent development and regulatory review stages. This consolidation of resources and expertise is expected to accelerate the program's progress and enhance its chances of success in a competitive market.

The medical device sector, particularly in the domain of cardiovascular treatments, is witnessing significant innovation and investment. As companies like Jaguar LAA emerge with specialized technologies, the landscape for AFib management is evolving. The focus on minimally invasive procedures aligns with broader trends in healthcare aimed at improving patient outcomes while reducing recovery times. The successful advancement of the Laminar program could set a new standard in LAA closure techniques, potentially influencing treatment protocols and patient care strategies in the future.

Overall, this acquisition underscores the growing interest in developing innovative solutions for complex medical conditions such as AFib. As Jaguar LAA moves forward with the Laminar program, the implications for the medical device industry could be substantial, paving the way for new treatment paradigms that prioritize both efficacy and patient safety. The ongoing evolution in this sector will be closely monitored by investors and healthcare professionals alike, as advancements in technology continue to reshape the treatment landscape.